PIAS1 and posterior cortical atrophy: Our study represents the first evidence to our knowledge at the organ level (3DP-POs) in patients supporting the sensitivity of SPOP-mutated PCa to PARP inhibitors, providing stronger evidence for the future clinical application of PARP inhibitors in PCa patients with SPOP mutations, as well as SPOP-WT, together with inhibitors targeting the CK2/PIAS1/SPOP signaling axis.